Zynex (ZYXI) Expected to Announce Earnings on Tuesday

Zynex (NASDAQ:ZYXI - Get Free Report) is projected to release its earnings data before the market opens on Tuesday, March 11th. Analysts expect Zynex to post earnings of $0.09 per share and revenue of $53.65 million for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.

Zynex Stock Performance

Shares of Zynex stock traded up $0.08 during trading on Friday, reaching $7.35. The company's stock had a trading volume of 49,406 shares, compared to its average volume of 70,648. The business's 50-day moving average price is $7.75 and its 200-day moving average price is $8.03. The firm has a market cap of $234.07 million, a PE ratio of 49.00 and a beta of 0.81. Zynex has a 52 week low of $7.00 and a 52 week high of $13.19. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price target on shares of Zynex in a research note on Friday, December 6th.

Insider Activity at Zynex

In related news, CFO Daniel J. Moorhead sold 10,000 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.15, for a total value of $71,500.00. Following the completion of the transaction, the chief financial officer now owns 10,050 shares of the company's stock, valued at $71,857.50. The trade was a 49.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 30,000 shares of company stock valued at $227,100 over the last quarter. 52.13% of the stock is owned by corporate insiders.

Remove Ads

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.